The Clinic Studies Of Serum S100 Protein Combined With Tissue Polypeptide Specific Antigen In Patients With Malignant Melanoma, Lung Cancer, Breast Cancer And Hepatocellular Carcinoma

Objective:1. To determine the normal level and to observe the distribution of serum S100 protein by ELISA.2. To investigate the expression of serum S100 protein as well as TPS in malignant melanoma.3. To assess the value of serum S100 protein combined with TPS in the early diagnosis,predicting relapse and metastasis,monitoring and prognosis of malignant melanoma.4. To study the expression of serum S100 protein in breast cancer,lung cancer as well as primary hepatocellular carcinoma.Methods1. The levels of serum S100 protein and TPS were determined with ELISA.2. The diagnosis effectiveness and clinical values of serum S100 protein and TPS were assessed by diagnosis test.3. To analyse the clinical values of serum S100 protein combined with TPS in the diagnosis,monitoring and prognosis of those people suffered from malignant melanoma,breast cancer,lung cancer,primary hepatocellular carcinoma and benign dermatogic disease,respectively.Results1. the distribution of serum S100 protein manifested negative skewness,and the median level was 0.026ug/L,95% confidence interval(95% CI) was [0,0.105]ug/L. It was thought to be abnormal when the level of Serum S100 protein>0.105ug/L.2. Controlled to the normal healthy group,the diagnostic Se of S100 protein and TPS was 32% and 21%,and the Sp was 95% and 90% respectively. There was no significant difference on the relationship between the diagnostic Se of S100 protein and TPS (P>0.05,paired x2 test). It was more sensitive but less special when combined with TPS.3. The positive rate and level of the serum S100 protein became higher when the disease advanced.4. The level of serum S100 protein before treatment could fortell the reaction to the therapy. The patients who owned higher levels got less effort.5. The levels of serum S100 protein and TPS in 15 patients with advanced lung cancer were 0.019ug/L - 0.54ug/L,33.2 U/L -234U/L,respectively. The positive rates of them were 0,73%(11/15),respectively. There were no significant differences between those patients regardless of metastatic brain cancers from lung as well as whose brains treated by radiotherapy or not (F>0.05,Wilcoxon rank sum test).6. The median levels of S100 protein and TPS in patients with 20 breast cancer were 0.024ug/L(<0.01ug/L-0.167ug/L),135U/L(0.3 U/L- 1200U/L),respectively,while the positive rates of them were 15%(3/20),50%( 10/20),respectively.7. The median levels of S100 protein and IPS in 22 patients with hepatocellular carcinoma were 0.011ug/L(<0.01ug/L-0.187ug/L),737.7U/L(0.2U/L- 1200U/L),respectively,while the positive rates of them were 5% (1/22),86%( 19/22),respectively.Conclusions1. Serum S100 protein is highly expressed in malignant melanoma.2. The positive rate and level of the serum S100 protein will become higher when the disease advances.3. Used to monitor the malignant melanoma patients,the level of serum S100 protein can reflect the effect of treatment and the progress of malignant melanom as well as predict recurrence and metastasis.4. S100 protein combined with TPS is more sensitive than S100 protein alone in the diagnosis of malignant melanoma. S100 protein is more sensitive and special than TPS.5. The high levels of serum S100 protein reveal recurrence,metastasis and bad prognosis,especially when it rises progressively. However the effect of TPS is not obvious.6. The serum levels of serum S100 protein in the patients with hepatocellular carcinoma,breast cancer and lung cancer (including brain metastatic cancer) do not appear high obviously. They cannot reflect the state and prognosis of these diseases. The diagnostic values are limited.